Lab-testing group ALS's FY27 guidance looks credible to Jefferies, but not overly demanding. ALS expects mid-to-high single-digit revenue growth in FY27. It estimates the earnings risk from the Middle East conflict at A$5 million-A$10 million. "We see scope for stronger revenue and margin expansion from FY28 onward," analyst John Campbell says. That partly reflects AI and automation initiatives, while activity among junior miners is picking up. Also, ALS should get a full-year contribution from its new Sydney and Lima laboratories. Jefferies retains a hold call on ALS and lifts its price target by 6.1% to A$24.40/share. ALS ended Monday at A$21.83. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
May 18, 2026 18:43 ET (22:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.